|
|
| | ARQ 092 Basic information |
| Product Name: | ARQ 092 | | Synonyms: | ARQ092 HCl;Miransertib (ARQ 092) HCl;ARQ092 Hydrochloride;Miransertib HCl;Miransertib HCl (ARQ 092);3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine hydrochloride;MK-7075);Miransertib hydrochloride | | CAS: | 1313883-00-9 | | MF: | C27H25ClN6 | | MW: | 468.99 | | EINECS: | | | Product Categories: | | | Mol File: | 1313883-00-9.mol |  |
| | ARQ 092 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO: 75 mg/mL (159.92 mM);Ethanol: 4 mg/mL (8.53 mM) | | form | Solid | | color | Light yellow to brown | | Water Solubility | Water: Insoluble |
| | ARQ 092 Usage And Synthesis |
| Uses | Miransertib hydrochloride (ARQ-092 hydrochloride) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib hydrochloride is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research[1]. Miransertib hydrochloride is effective against Leishmania[2]. | | Synthesis | Step 4: Tert-butyl (1 -(4-(2-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3-yl)phenyl)cyclobutyl)carbamate (4.1 g) was dissolved in dichloromethane (100 mL), and a dioxane solution (20 mL) of 4.0 M HCl was slowly added. The reaction mixture was stirred at room temperature for 2.5 hours. After completion of the reaction, ether (50 mL) was added to the suspension and the solid was collected by filtration to afford 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine hydrochloride (4.032 g, white solid). The product was characterized by 1H NMR (DMSO-d6, 400 MHz) and LCMS: 1H NMR δ 8.94 (s, 3H), 8.47 (bs, 1H), 8.38 (d, J = 8.8 Hz, 1H), 8.19-8.15 (m, 1H), 8.10-8.03 (m, 3H), 7.93-7.88 (m, 1H), 7.76 (d, J = 8.4 Hz, 1H), 7.69 (d, J = 8.4 Hz, 2H), 7.52-7.40 (m, 3H), 6.92 (t, J = 7.6 Hz, 1H), 2.70-2.57 (m, 4H), 2.29-2.20 (m, 1H), 1.90-1.80 (m, 1H); LCMS: m/z 433 [M + H]+. Calculated elemental analysis (C29H27ON7-3.06HCl-0.01C4H8O2-0.03C4H10O): C 59.61, H 5.28, N 15.36; measured values: C 59.62, H 5.05, N 15.36. | | in vivo | Miransertib (ARQ-092; Compound 21a) shows good absolute oral bioavailability in rats (5 mg/kg) and monkeys (10 mg/kg) with F values of 62% and 49%, respectively. The half-life is longer in rats compared to monkeys with t1/2 values of 17 h in rats versus 7 h in monkeys. The Cmax is 198 ng/mL and 258 ng/mL and the AUCinf was 5496 hng/mL and 2960 hng/mL in rats and monkeys, respectively[1].
Miransertib (ARQ-092; Compound 21a) inhibits tumor growth in a human xenograft mouse model of endometrial adenocarcinoma[1]. | | IC 50 | Akt1: 2.7 nM (IC50); Leishmania; Akt3: 8.1 nM (IC50); Akt2: 174 nM (IC50); Akt1 E17K mutant | | References | [1] Lapierre JM, et al. Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor. J Med Chem. 2016 Jul 14;59(13):6455-69. DOI:10.1021/acs.jmedchem.6b00619
[2] Devki Nandan, et al. Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania. PLoS One. 2018 Nov 6;13(11):e0206920. DOI:10.1371/journal.pone.0206920 |
| | ARQ 092 Preparation Products And Raw materials |
|